ArticleAntibiotics (Basel, Switzerland)2024
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Potentiation of Penicillin G and Selected β-Lactams with Quercetin Against Multidrug-Resistant Bacteria: Mechanistic Insights, Antibacterial Phytochemicals, and Toxicity Evaluation.International journal of molecular sciences · 2026Article
- Formulation ofCurrent issues in molecular biology · 2026Article
- GC-MS based bioactive profiling of Phyllanthus niruri and its antibacterial potential through experimental and computational studies.PloS one · 2026Article
- Antibacterial and Synergistic Effects ofAntibiotics (Basel, Switzerland) · 2025Article
- Herbal Immunostimulants and Their Phytochemicals: ExploringPlants (Basel, Switzerland) · 2025Review
- Article
- Phytochemical Analysis and Antimicrobial Activity ofMicroorganisms · 2024Article
- Combinations ofAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a global public health threat caused by the misuse and overuse of antibiotics. It leads to infections becoming difficult to treat, causing serious illness, disability, and death. Current antibiotic development is slow, with only 25% of current antibiotics exhibiting novel mechanisms against critical pathogens. Traditional medicinal plants' secondary metabolites offer potential for developing novel antibacterial compounds. These compounds, often with strong antimicrobial activity, can be used to develop safe and effective antibacterial chemotherapies. This study investigated the antibacterial activity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.